What it's for (Indications)
- This combination vaccine is indicated for active primary immunization against Diphtheria, Tetanus, Acellular Pertussis (whooping cough), Hepatitis B, and invasive diseases caused by *Haemophilus influenzae* type b (Hib) in infants and young children.
- It is administered as part of a routine immunization schedule to establish robust immunity against these five serious infectious diseases, which can lead to severe morbidity and mortality, especially in unvaccinated populations.
- The vaccine aims to protect susceptible individuals by inducing specific humoral and cellular immune responses, thereby significantly reducing the incidence and severity of these conditions during childhood.
- This comprehensive protection is crucial for public health and individual well-being, contributing to herd immunity efforts and disease eradication goals against prevalent pediatric infections.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dosage for this combination vaccine is a single 0.5 mL dose administered intramuscularly. The primary immunization course typically consists of three doses given according to national and local immunization schedules, commonly at 6, 10, and 14 weeks of age, or at 2, 4, and 6 months of age, depending on the specific program and guidelines. Subsequent booster doses may be required later in childhood to maintain long-term protection, aligning with established public health recommendations for DTaP, Hepatitis B, and Hib components. The deltoid muscle is the preferred site for administration in older infants and children, while the anterolateral thigh is commonly used for younger infants. Strict adherence to the recommended dosage and schedule is paramount for achieving optimal protective immunity and maximizing vaccine effectiveness. |
Safety & Warnings
Common Side Effects
- Commonly reported side effects include transient local reactions at the injection site such as pain, redness (erythema), swelling, and induration, which typically resolve within 24-48 hours.
- Systemic reactions may include fever (low-grade), irritability, drowsiness, fussiness, loss of appetite, and occasional vomiting or diarrhea.
- Less common but more serious adverse events can occur, such as persistent, inconsolable crying lasting for several hours, hypotonic-hyporesponsive episodes (HHE), or seizures (febrile or afebrile).
- Anaphylaxis, a severe and life-threatening allergic reaction, is extremely rare but possible; therefore, appropriate medical monitoring and emergency treatment facilities should always be available during and immediately following vaccination.
- Parents and caregivers should be advised to monitor for these reactions and seek medical attention for any concerns, particularly if symptoms are severe or persistent.
Serious Warnings
- Black Box Warning: **SERIOUS WARNINGS: Anaphylaxis and Neurological Events** While extremely rare, serious adverse events can occur following vaccination. **Anaphylaxis**, a severe and potentially life-threatening allergic reaction, is a medical emergency that requires immediate intervention. Healthcare providers must have epinephrine and other appropriate medical treatment readily available to manage acute allergic reactions, and patients should be observed for a period following vaccination. Individuals with a history of severe allergic reaction to any component of this vaccine or to a previous dose are strictly contraindicated. Furthermore, vaccination should be carefully considered and discussed with a specialist for individuals with a history of specific neurological conditions. Encephalopathy occurring within 7 days of a previous DTP/DTaP dose that is not attributable to another cause is a contraindication. The potential for neurological adverse events, though exceedingly rare and often without established causality to the vaccine, necessitates careful pre-screening for progressive neurological disorders. Parents and caregivers should be fully informed about these potential serious, albeit rare, risks and instructed on when to seek immediate medical attention.
- Vaccination should be postponed in individuals experiencing an acute severe febrile illness; a minor infection, such as a common cold, is generally not a contraindication.
- Care should be exercised when administering this vaccine to individuals with a history of bleeding disorders or thrombocytopenia, as intramuscular injection could lead to hemorrhage; pressure should be applied to the injection site without rubbing.
- As with all injectable vaccines, appropriate medical treatment and supervision must always be readily available in case of a rare anaphylactic reaction following administration.
- The potential risk of apnea and the need for respiratory monitoring for 48-72 hours should be considered when administering the primary immunization series to very premature infants (born ≤28 weeks of gestation), especially those with a history of respiratory immaturity.
- The vaccine should under no circumstances be administered intravenously.
- Patients with neurological conditions should be carefully evaluated before vaccination to assess the benefit-risk profile.
How it Works (Mechanism of Action)
This combination vaccine confers active immunity against Diphtheria, Tetanus, Pertussis, Hepatitis B, and *Haemophilus influenzae* type b by introducing purified antigens from these pathogens into the body. The Diphtheria and Tetanus toxoids are chemically detoxified bacterial toxins that retain their immunogenicity, stimulating the production of neutralizing antibodies against the actual toxins. The Acellular Pertussis components (Pertussis toxoid, Filamentous Hemagglutinin, and Pertactin) induce an immune response against *Bordetella pertussis* virulence factors. The Hepatitis B surface antigen (HBsAg) elicits protective antibodies against the Hepatitis B virus. The *Haemophilus influenzae* type b (Hib) conjugate component, consisting of the capsular polysaccharide covalently linked to a protein carrier, induces T-cell-dependent immune responses, leading to the production of anti-PRP antibodies. These elicited antibodies and cellular immune responses provide specific, long-lasting protection against subsequent exposure to the respective pathogens, preventing disease or significantly mitigating its severity.
Commercial Brands (Alternatives)
No other brands found for this formula.